{"id":60367,"date":"2024-02-28T06:45:31","date_gmt":"2024-02-28T06:45:31","guid":{"rendered":"https:\/\/medsname.com\/q-siz-sr-400\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"q-siz-sr-400","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/q-siz-sr-400\/","title":{"rendered":"Q-Siz SR 400"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Q-Siz SR 400?<\/h3>\n
\n

Q-Siz SR 400<\/strong> tartalmaz quetiapine 400 mg (extended-release (once-daily))<\/strong> from a WHO-GMP certified manufacturer (Healing Pharma) — an atypical antipsychotic<\/strong> with broad use across schizophrenia, bipolar disorder, and treatment-resistant depression. Mechanism: D2 + 5-HT2A<\/sub> antagonism plus prominent H1<\/sub> antihistamine action (heavy sedation) plus alpha-1 blockade (orthostasis). Doses span a huge range by indication: 25–100 mg HS<\/strong> (off-label insomnia, anxiety adjunct — controversial), 300–800 mg\/day<\/strong> (schizophrenia, bipolar mania), 150–300 mg\/day<\/strong> (bipolar depression, MDD adjunct). Major class warnings<\/strong>: metabolic syndrome (weight, glucose, lipids — class effect), heavy sedation, orthostatic hypotension, QT prolongation, EPS (lower than first-generation antipsychotics), and FDA black box for elderly dementia mortality<\/strong>.<\/p>\n<\/div>\n

\nMit kapsz a MedsBase-n\u00e1l:<\/strong> WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3 \u00b7 Diszkr\u00e9t csomagol\u00e1s \u00b7 Vil\u00e1gszerte sz\u00e1ll\u00edt\u00e1s \u00b7 1.400+ hiteles\u00edtett v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a>\n<\/div>\n

\ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n

Mi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n

Generikus gy\u00f3gyszereink WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3kt\u00f3l sz\u00e1rmaznak, \u00e9s diszkr\u00e9t, egyszer\u0171 csomagol\u00e1sban sz\u00e1ll\u00edtjuk \u0151ket vil\u00e1gszerte \u2014 a csomagon nem szerepel a gy\u00f3gyszer neve. A k\u00e1rty\u00e1s fizet\u00e9sek egy szab\u00e1lyozott feldolgoz\u00f3n kereszt\u00fcl t\u00f6rt\u00e9nnek (a sz\u00e1mlale\u00edr\u00e1sok egy szab\u00e1lyozott k\u00e1rtyafizet\u00e9si feldolgoz\u00f3t tartalmaznak \u2014 soha nem \u201cMedsBase\u201d vagy b\u00e1rmilyen gy\u00f3gyszer neve). Kriptovalut\u00e1t \u00e9s SEPA banki \u00e1tutal\u00e1st is elfogadunk. Minden rendel\u00e9st a Reshipment Assurance Policy biztos\u00edt\u00e9k fedez.<\/p>\n<\/div>\n

Important — this is not a situational-anxiety medication.<\/strong> Q-Siz SR 400 is a atypical antipsychotic<\/strong>, prescribed and titrated over weeks for schizophrenia, bipolar mania and depression, bipolar maintenance, and adjunctive treatment of major depressive disorder<\/strong>. It is nem<\/strong> the right drug for acute, performance-related anxiety (flying, public speaking, exams) — for those use cases beta-blockers (propranolol), benzodiazepines, or hydroxyzine are clinically appropriate. If you do not have a diagnosed mood, anxiety, or psychiatric disorder, do not start this medication.<\/div>\n
FDA black-box warning — elderly dementia mortality.<\/strong> All antipsychotics (atypical and conventional) carry an FDA black-box warning for increased mortality when used to treat dementia-related psychosis or behavioural disturbance in elderly patients. This medication is nem hagyta j\u00f3v\u00e1<\/strong> for dementia-related symptoms.<\/div>\n

What Is Q-Siz SR 400?<\/h2>\n

Q-Siz SR 400 is an oral extended-release (once-daily) tablet of quetiapine fumarate 400 mg<\/strong> manufactured by Healing Pharma. Quetiapine (US brand Seroquel IR \/ Seroquel XR<\/strong>) is an atypical (second-generation) antipsychotic launched by AstraZeneca in 1997. It is a D2<\/sub> \u00e9s 5-HT2A<\/sub> antagonist with strong H1<\/sub> antihistamine and moderate alpha-1 antagonist activity<\/strong>. The H1<\/sub> blockade drives the prominent sedation; the alpha-1 blockade drives orthostatic hypotension; the 5-HT2A<\/sub> antagonism reduces extrapyramidal side-effect risk compared with first-generation antipsychotics.<\/p>\n

The XR (extended-release)<\/strong> formulation allows once-daily dosing and reduces peak plasma concentrations — less peak sedation immediately after the dose, but the overall daily AUC is similar to IR. XR cannot be split, crushed, or chewed.<\/p>\n

J\u00f3v\u00e1hagyott indik\u00e1ci\u00f3k<\/h2>\n
    \n
  • Schizophrenia<\/strong> — acute and maintenance<\/li>\n
  • Bipolar mania<\/strong> — acute (monotherapy or with lithium \/ valproate)<\/li>\n
  • Bipolar depression<\/strong> — one of the few drugs FDA-approved for this; first-line in bipolar I depression<\/li>\n
  • Bipolar maintenance<\/strong> — with lithium or valproate<\/li>\n
  • Adjunctive treatment of MDD<\/strong> — XR formulation, 150–300 mg\/day with an antidepressant<\/li>\n
  • Off-label: insomnia (low dose 25–50 mg), anxiety (controversial — metabolic risk for non-psychotic anxiety), agitation in dementia (used with caution given black-box warning)<\/li>\n<\/ul>\n

    D\u00f3zisoz\u00e1s indik\u00e1ci\u00f3 szerint<\/h2>\n\n\n\n\n\n\n\n\n\n\n
    Agoprex is a 25 mg agomelatine tablet supplied by Sun Pharma. Agomelatine is mechanistically unique among antidepressants: it acts as an agonist at melatonin MT1 and MT2 receptors and an antagonist at 5-HT2C serotonin receptors. The dual mechanism resynchronises disrupted circadian rhythms (a feature of major depression) while indirectly increasing dopamine and noradrenaline release in the frontal cortex.<\/th>\nKezel\u00e9s ind\u00edt\u00e1sa<\/th>\nIndications and dosing<\/th>\nMaxim\u00e1lis<\/th>\nMegjegyz\u00e9sek<\/th>\n<\/tr>\n<\/thead>\n
    Schizophrenia (XR)<\/td>\n50 mg BID (or 300 mg HS XR)<\/td>\n400–800 mg\/day<\/td>\n800 mg\/day<\/td>\nTitrate over 4–7 days; XR allows once-daily HS dosing<\/td>\n<\/tr>\n
    Bipolar mania (acute)<\/td>\n100 mg\/day × day 1, increase by 100 mg\/day<\/td>\n400–800 mg\/day<\/td>\n800 mg\/day<\/td>\nRapid titration to control mania<\/td>\n<\/tr>\n
    Bipolar depression<\/td>\n50 mg HS × day 1, then 100, 200, 300<\/td>\n300 mg\/day at bedtime<\/td>\n300 mg\/day<\/td>\nStandard maximum for this indication<\/td>\n<\/tr>\n
    MDD adjunct (XR only)<\/td>\nMax<\/td>\n150–300 mg\/day<\/td>\n300 mg\/day<\/td>\nAdd to existing antidepressant; sedation often dose-limiting<\/td>\n<\/tr>\n
    Off-label insomnia<\/td>\n25–50 mg HS<\/td>\n25–50 mg HS<\/td>\n100 mg HS<\/td>\nControversial — metabolic risk for sleep dose makes this a poor first choice; reserve for patients who have failed multiple alternatives<\/td>\n<\/tr>\n
    Id\u0151s<\/td>\n25–50 mg\/day, slower titration<\/td>\n\u2014<\/td>\nConsider 200–300 mg\/day max<\/td>\nGreater sedation and orthostasis — falls risk<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Mell\u00e9khat\u00e1sok<\/h2>\n

    Side-effect profile by mechanism<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    \u2014 ha 20 munkanapon bel\u00fcl nem \u00e9rkezik meg, ingyenesen \u00fajrak\u00fcldj\u00fck. Ez az egyetlen h\u00e1ny\u00e1sg\u00e1tl\u00f3 kombin\u00e1ci\u00f3, amely FDA A kateg\u00f3ri\u00e1j\u00fa st\u00e1tusszal rendelkezik a terhess\u00e9g alatt, \u00e9s az ACOG, a NICE \u00e9s a SOGC els\u0151vonalbeli aj\u00e1nl\u00e1sa a terhess\u00e9gi h\u00e1nyinger \u00e9s h\u00e1ny\u00e1s kezel\u00e9s\u00e9re.<\/th>\nH\u00e1nyinger, hasi f\u00e1jdalom, fejf\u00e1j\u00e1s, sz\u00e9d\u00fcl\u00e9s, gynekomastia (f\u00e9rfiakn\u00e1l, d\u00f3zisf\u00fcgg\u0151)<\/th>\nNotes \/ management<\/th>\n<\/tr>\n<\/thead>\n
    Metabolic (5-HT2C<\/sub> + H1<\/sub> appetite drive)<\/td>\nWeight gain (often significant), increased blood glucose \/ new-onset diabetes, dyslipidaemia<\/td>\nClass warning — baseline weight, BP, fasting glucose, lipids; reassess at 3 months and annually<\/td>\n<\/tr>\n
    H1<\/sub> blockade<\/td>\nHeavy sedation, drowsiness<\/td>\nUseful at bedtime; often limiting during the day. Less peak sedation with XR<\/td>\n<\/tr>\n
    Alpha-1 blockade<\/td>\nOrthosztatikus hypot\u00f3nia, sz\u00e9d\u00fcl\u00e9s<\/td>\nSlow titration; check lying \/ standing BP<\/td>\n<\/tr>\n
    Anticholinergic (mild)<\/td>\nDry mouth, constipation<\/td>\nLess than olanzapine<\/td>\n<\/tr>\n
    D2<\/sub> blockade<\/td>\nExtrapyramidal symptoms (akathisia, parkinsonism, dystonia)<\/td>\nLower than first-generation antipsychotics; akathisia at higher doses<\/td>\n<\/tr>\n
    Egy\u00e9b<\/td>\nQT-intervallum meghosszabbod\u00e1s<\/td>\nBaseline ECG; caution with other QT-prolonging drugs<\/td>\n<\/tr>\n
    Ritka<\/td>\nTard\u00edv dyskinesia<\/td>\nLower risk than typical antipsychotics but real with long-term use<\/td>\n<\/tr>\n
    Ritka<\/td>\nNeuroleptic malignant syndrome<\/td>\nHyperthermia, rigidity, autonomic instability — emergency<\/td>\n<\/tr>\n
    Ritka<\/td>\nHyperprolaktinaemia<\/td>\nLess than risperidone<\/td>\n<\/tr>\n
    Ritka<\/td>\nCataracts<\/td>\nLens monitoring controversial; some clinicians order 6-monthly slit-lamp exam<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Gy\u00f3gyszerk\u00f6lcs\u00f6nhat\u00e1sok<\/h2>\n

    CYP3A4 szubsztr\u00e1t<\/strong>: levels rise with strong inhibitors (ketoconazole, ritonavir, clarithromycin) — reduce dose. Levels fall with strong inducers (rifampin, phenytoin, carbamazepine) — loss of efficacy.<\/p>\n

    Additive sedation<\/strong>: alcohol, benzodiazepines, opioids, sedating antidepressants.<\/p>\n

    QT-intervallum meghosszabbod\u00e1s<\/strong>: caution with citalopram (high dose), methadone, ondansetron, fluoroquinolones, ziprasidone.<\/p>\n

    Antihipertenz\u00edv szerek<\/strong>: additive orthostasis with alpha-blockers, ACE inhibitors, diuretics.<\/p>\n

    Antikolinerg terhel\u00e9s<\/strong>: additive with diphenhydramine, oxybutynin.<\/p>\n

    Metabolic Monitoring<\/h2>\n

    All atypical antipsychotics carry a class warning for metabolic syndrome — weight gain, dyslipidaemia, and impaired glucose tolerance. Quetiapine sits in the higher-risk group (with olanzapine and clozapine). Standard monitoring: baseline + 3 months + annually<\/strong>: weight \/ BMI, waist circumference, fasting glucose or HbA1c, fasting lipid panel, blood pressure. Consider a switch to a lower-metabolic-risk agent (aripiprazole, lurasidone, ziprasidone) if weight \/ glucose deteriorates.<\/p>\n

    Gyakran Ism\u00e9telt K\u00e9rd\u00e9sek<\/h2>\n

    How long does Q-Siz SR 400 take to work?<\/h3>\n

    Acute psychosis or mania symptoms often respond within days; full benefit at 4–6 weeks. Bipolar depression response typically appears at 1–3 weeks at the 300 mg target.<\/p>\n

    Why is Q-Siz SR 400 used for sleep?<\/h3>\n

    Quetiapine 25–50 mg HS produces heavy sedation through H1<\/sub> blockade. Off-label sleep use has become widespread but is controversial — metabolic side effects accumulate even at low dose, and safer hypnotics exist.<\/p>\n

    Will Q-Siz SR 400 make me gain weight?<\/h3>\n

    Likely yes — quetiapine is one of the more weight-gain-prone atypicals. Average weight gain at therapeutic doses is 4–7 kg over 12 months; some patients gain considerably more. Lifestyle interventions help; switching to aripiprazole or lurasidone may be needed if weight becomes problematic.<\/p>\n

    Is Q-Siz SR 400 safe in elderly patients with dementia?<\/h3>\n

    FDA black-box warning for increased mortality in elderly with dementia-related psychosis or behavioural disturbance. Use only when behavioural and non-pharmacological strategies have failed and the symptoms are severe; lowest dose, shortest duration, with informed consent of family.<\/p>\n

    Can I drink alcohol on Q-Siz SR 400?<\/h3>\n

    Avoid — additive sedation and orthostasis. Even moderate alcohol substantially increases sedation and falls risk.<\/p>\n

    What is the difference between IR and XR quetiapine?<\/h3>\n

    IR peaks at 1–2 hours; XR peaks at ~6 hours and allows once-daily dosing. IR has more peak sedation just after the dose; XR has a smoother profile. Daily AUC is similar at equivalent doses.<\/p>\n

    Will Q-Siz SR 400 cause extrapyramidal side effects?<\/h3>\n

    Quetiapine has the lowest EPS risk among atypicals along with clozapine. Akathisia at higher doses is the most common motor side effect; tardive dyskinesia risk exists with long-term use but is much lower than first-generation antipsychotics.<\/p>\n

    Is Q-Siz SR 400 safe in pregnancy?<\/h3>\n

    Limited data — quetiapine is one of the better-studied atypicals in pregnancy. Continuation is reasonable when needed for serious mental illness; first-trimester exposure does not appear to increase major malformation rates above baseline.<\/p>\n

    Can I stop Q-Siz SR 400 abruptly?<\/h3>\n

    Better to taper, especially after long-term use — abrupt discontinuation can produce withdrawal dyskinesia, insomnia, nausea, sweating, and rebound psychosis or mania. Reduce by 25–50 mg every 1–2 weeks.<\/p>\n

    How should Q-Siz SR 400 be stored?<\/h3>\n

    Store at 15–30 °C in the original blister packaging, away from moisture and sunlight. Keep out of reach of children.<\/p>\n

    Orvosi felel\u0151ss\u00e9gi nyilatkozat:<\/strong> Information on this page is intended for adults using prescribed psychiatric medication and is not a substitute for individualised medical care. Antidepressants, antipsychotics, and related medications can interact with other drugs, alcohol, and pre-existing conditions. Discuss any new medication, dose change, or planned discontinuation with a qualified prescriber. If you experience suicidal thoughts, mania, severe akathisia, signs of serotonin syndrome (high fever, confusion, muscle rigidity, rapid heart rate), or neuroleptic malignant syndrome, seek emergency care immediately.<\/div>\n

    <\/p>\n

    Kapcsol\u00f3d\u00f3 alternat\u00edv\u00e1k<\/h3>\n

    Egy\u00e9b term\u00e9kek a Kr\u00f3nikus betegs\u00e9gek<\/strong> v\u00e1s\u00e1rl\u00f3k \u00e1ltal szint\u00e9n megtekintett term\u00e9kek:<\/p>\n